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Abstract The synthesis of a porous polysulfone (PSU)
coating for use in drug delivery applications is pre-
sented. PSU can serve as a functional surface coating
for drug delivery vehicles, such as intraocular biomicro-
robots. The coatings can be applied using spin coating
or dip coating. The porosity is introduced by selectively
dissolving calcium carbonate nanoparticles embedded
in the bulk polymer. The network of pores thus formed
increases by a factor of thirty the amount of Rhodamine
B (model drug) that can be loaded and by a factor
of fifteen the amount that can be released. The films
do not affect cell viability and exhibit poor cell adhe-
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1 Introduction
Drug delivery systems (DDS) are designed to enhance
the efficacy of therapeutic agents by enabling their
targeting and controlled release. An ideal DDS de-
livers medication exclusively to the diseased part of
the body and releases it in a controlled manner. DDS
have already enhanced the performance of many ex-
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completely new therapies as well (LaVan et al. 2003).
In recent years, they have been miniaturized to the
micro/nanoscale with the aim of improving the phar-
macokinetics, biodistribution, and solubility of drugs
(Allen and Cullis 2004). These efforts in scaling down
have created various challenges. For example, the de-
vices must be able to accommodate a clinically relevant
amount of drug, must comply with biocompatibility and
non-toxicity standards, and methods must be developed
to measure their performance. Drug delivery has now
become a multidisciplinary science where chemistry,
microfabrication, nanotechnology, biology, and medi-
cine all converge. Broadly, DDS that use nanostruc-
tured or nanoscale materials can be divided into two
categories (LaVan et al. 2003; Allen and Cullis 2004).
– Therapeutic agents bound to nanoscale platforms
such as nanoparticles, liposomes or micelles that
can be introduced parenterally.
– Implants with nanoporous materials that act as
reservoirs releasing the drug in a sustained manner.
Nanoparticles are especially suitable for DDS appli-
cations because of their large surface-area-to-volume
ratio that helps in binding a large amount of drug
(De Jong and Borm 2008). The nanoparticle platform
can be made of inorganic substances such as gold
(Paciotti et al. 2004), iron (Gupta and Gupta 2005),
and silica (Liong et al. 2008). Apart from the thera-
peutic agents, other molecules or chemical ligands are
also attached to these particles. They help in targeting
specific tissues, improve the imaging of these particles
and help the particles stay in circulation for a longer
time inside the body. Nanoparticle-based DDS made
of liposomes and biodegradable polymers are gaining
more attention because of their efficiency in penetrat-
ing the fenestrated endothelium of tumors due to the
enhanced permeability and retention effect (EPR, Peer
et al. 2007). Once they gain access to tumors, they
persist and release their contents and raise local drug
concentrations inside the tumors. However, despite the
vast amount of scientific literature available, there are
lingering concerns about the toxicity of nanoparticle-
based DDS. Due to the novel nature and extremely
small size (ranging between 1 and 100 nm) of these
materials, their long term effects on the body are not
yet well understood, thus restricting their commercial
use (Lewinski et al. 2008).
Advances in MEMS fabrication technology has al-
ready resulted in the commercialization of lab-on-a-
chip devices for medical diagnosis and pushed forward
the development of scaffolds for tissue engineering,
stents, and implantable drug delivery devices (Tao and
Desai 2002). These implants may release the encap-
sulated drug either due to changes in the implants’
surroundings or due to external triggers like magnetic
fields, light, or ultrasound (Sershen and West 2002).
Most of these systems demonstrate the use of poly-
mers and their interesting porous properties at the
micro/nanoscales. Due to their high surface-area-to-
volume ratio, nanoporous polymers show increased
adsorption of molecules and, therefore, can be used
in drug loading and release. In Yan et al. (2009),
nanoporous polymer membranes have proven to in-
crease the release of the model drug Rhodamine B by
a factor of two compared to their nonporous counter-
parts .
The use of a wirelessly guided microrobot has been
proposed for performing robotic surgery and for tar-
geted drug delivery (Nelson et al. 2010). Although
intended primarily for intraocular applications, the mi-
crorobot is envisaged for use in other parts of the
human body as well. It is made of magnetic materials
that are patterned using standard MEMS fabrication
techniques and can be precisely maneuvered in three-
dimensional space using a custom designed system
of electromagnets (Kummer et al. 2010). A wireless
intraocular oxygen sensor concept has been demon-
strated using this microrobot (Ergeneman et al. 2010).
For drug delivery applications, the surface area of the
microrobot has been identified as the factor limiting the
amount of drug that can be adsorbed or immobilized
onto it (Ergeneman et al. 2008). Implementing a porous
functional coating on the microrobot can increase its
drug loading capacity by increasing the surface area
of the device. For a fixed macroscopic volume of a
functional polymer coating, those which are porous
demonstrate an enhanced ability to adsorb and re-
lease Rh-B than planar coatings of the same polymer
(Sivaraman et al. 2010).
In this work, we present the development of a porous
coating made of polysulfone (PSU) that is envisaged
for use in targeted drug delivery applications using
the microrobot. PSU is a high performance biocom-
patible polymer (Wenz et al. 1990) which is already
in use in medical equipment such as blood dialysis
membranes (Gastaldello et al. 2001). The application
of PSU capillary fibers for intraocular drug delivery has
been reported (Rahimy et al. 1994). To produce the
coating, a suspension of calcium carbonate (CaCO3)
nanoparticles in PSU was coated onto a substrate and
the nanoparticles were selectively removed resulting in
a network of nanometer-sized pores in the PSU. Such
a protocol has been successfully used in Luechinger
et al. (2010) to produce nanoporous membranes of
silver. Apart from the enhanced drug adsorption and
release of Rh-B from these porous PSU coatings, the
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viability and adhesion of cells on these coatings are also
investigated in this work.
2 Materials and methods
2.1 Synthesis of the CaCO3 nanoparticles by flame
spray pyrolysis
The CaCO3 nanoparticles were synthesized using the
flame spray pyrolysis (FSP) technique. Although a rel-
atively new technique, FSP can produce nanoparticles
with a wide and complex range of chemical compo-
sitions. In the FSP method, a liquid precursor in the
form of fine droplets is fed to a flame in a reactor.
This causes a reaction between the components of the
precursor, thus, producing nanoparticles. The chemical
composition of the precursor and the composition and
flow of the fuel mixture producing the flame are impor-
tant parameters in the FSP process (Maedler et al. 2002;
Stark and Pratsinis 2002).
The CaCO3 nanoparticles were synthesized
by adopting the protocol given in Huber et al.
(2005). A precursor consisting of 9 wt% calcium
hydroxide (Ca(OH)2, 99.9%, Aldrich) dissolved
in equivalent volumes of 2-ethylhexanoic acid
(CH3(CH2)3CH(C2H5)CO2H, ≥95%, Fluka) and
xylene (C6H4(CH3)2, 96%, Riedel de Haen). The
precursor was fed to a methane/oxygen (CH4/O2)
flame sustained by feeding methane and oxygen at
inlet rates of 9 ml.min−1 and 9 l.min−1, respectively. To
collect the nanoparticles, a glass fiber filter (Whatmann
Ltd., USA) was mounted in the reactor above the
flame. The off gas containing the nanoparticles was
passed through the filter using a vacuum pump (Busch
S.A., Switzerland).
2.2 Characterization of CaCO3 nanoparticles
The diameters of the particles were in a range of 20–
50 nm (Fig. 1, Philips CM 12, Philips CM 12, Philips,
the Netherlands). X-ray diffraction (XRD) measure-
ments performed using Cu Kα radiation (X’Pert Pro
MPD, Pananalytical, The Netherlands) confirmed the
crystalline nature of the particles. Thermo-gravimetric
Analysis (TGA) experiments (Fig. 2) using 32 mg of
the powder resulted in a change in mass of 35%. Upon
heating, calcium carbonate decomposes to yield cal-
cium oxide (CaO) and carbon dioxide (CO2) gas as
shown in Eq. 1. It was determined that the particles
Fig. 1 Transmission electron micrograph of the flame synthe-
sized CaCO3 nanoparticles. The acceleration voltage used was
100 kV. The diameter of the particles was between 20 nm and
50 nm
consisted of 20 wt% of calcium oxide (CaO) and 80
wt% CaCO3.
CaCO3(s) → CaO(s) + CO2(g) (1)
2.3 Preparation of the PSU-CaCO3 composite films
A 15 wt% solution of PSU (Udel P-1700, Dolder AG,
Switzerland) in dichloromethane (CH2Cl2, J.T. Baker)
was prepared by stirring the components for 12 h at
room temperature. CaCO3 nanoparticles were added
to the PSU while maintaining the following ratios by
weight:
– CaCO3 : PSU = 1 : 1.105
– CaCO3 + PSU : CH2Cl2 = 1 : 17.5
Fig. 2 The thermogram of the CaCO3 nanoparticle powder. A
change in mass of 35% was observed when 32 mg of the powder
was used for the analysis
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The CaCO3 : PSU ratio was maintained guided by
the realization that too few particles would result in
them being too far apart in the polymer to form an
interconnected matrix, while a high concentration of
these particles would cause the coating to collapse
once these particles were dissolved. The CaCO3 +
PSU : CH2Cl2 ratio was important to ensure a suitable
viscosity of the particle-polymer mixture. The viscosity
and the coating parameters eventually determined the
thickness of the composite film. The particle-polymer
mixture was mixed in a vortexer and sonicated (1 min
@ 240 W and 24 kHz) to obtain a suspension that
remained stable for 12 h.
To synthesize the composite film, 500 μl of the
particle-polymer mixture was pipetted onto a square
silicon chip with an area of 2.25 cm2 and spin-coated
for 1 min at a speed of 1000 rpm and an acceleration
of 1000 rpm.s−1. The chip was then dried in air for 1
min and immersed in a 1% HCl solution for 5 min
to dissolve the CaCO3 particles. The bulk PSU films
were also prepared using these spin coating parameters
(Fig. 3). The morphology of the porous as well as bulk
PSU coatings were observed by SEM (Zeiss Leo 1530
Gemini, Carl Zeiss AG, Germany).
2.4 Rhodamine B loading and release
Rhodamine B (Rh-B) is a fluorescent molecule roughly
1.6 nm in size and has been widely used as a model drug
Fig. 3 Schematic of the preparation of porous PSU films. (a) The
gold substrate obtained by e-beam evaporation on silicon. (b)
The PSU-CaCO3 composite film obtained by dip coating or spin
coating. (c) The porous PSU film after the selective dissolution
of CaCO3 nanoparticles using HCl
to study the behavior of novel drug delivery systems
(Oh et al. 2008; Yan et al. 2009). Although it has little
clinical significance, the convenience of detecting it
through fluorescence spectrometry makes it a suitable
molecule to evaluate the drug loading performance of
porous coatings. For loading Rh-B, each coated chip
was immersed in a well plate containing 2 ml of the
dye solution (2 g.l−1 of Rh-B in phosphate buffered
saline (PBS), both from Sigma) per well for 18 h at
room temperature in a dark environment. The loosely
attached dye molecules were removed by washing the
chips three times with Millipore-Milli-Q water, each
cleaning step lasting 15 s.
The chips were then transferred into a new well
plate containing 750 μl of PBS solution per well and
stored in a dark environment. At the point of time
of measuring the amount of Rh-B released, the chips
were removed and transferred into a new well plate
containing 750 μl of PBS per well and stored in the
dark. From the PBS containing the released dye, 200 μl
was pipetted out into a 96-well microplate reader. This
procedure was repeated at 10 min intervals in the first
half hour and later at 30 min intervals until 4 h. The
fluorescence of the released Rh-B was measured by a
spectrophotometer (Tecan Infinite 200s, Tecan GmbH,
Germany). An excitation wavelength of 540 nm and
emission wavelength of 625 nm were used during the
fluorescence measurements. The experiments were re-
peated over 10 samples for each of the porous PSU and
the bulk PSU.
2.5 Estimation of amount of Rhodamine B loading
To determine the amount of Rh-B loaded, the samples
were prepared in exactly the same manner as in the
release experiments: i.e. they were immersed in 2 ml
of the dye solution (2 g.l−1 of Rh-B in PBS) for 18 h at
room temperature in a dark environment. The loosely
attached dye molecules were removed by washing the
samples three times with Millipore-Milli-Q water, each
cleaning step lasting 15 s. The washed samples were
placed in dark glass vials containing 2 ml of acetone
(CH3-CO-CH3, reagent grade, Sigma) and left undis-
turbed for 48 h. Acetone was chosen as the medium for
release because Rh-B is known to be more soluble in
acetone than in aqueous media. The acetone containing
the Rh-B was then transferred from the vials to a round
bottom flask. To ensure the complete release of Rh-B
from the membranes, they were further cleaned three
times with acetone. Each time, 2 ml of acetone was
pipetted into the vials, left standing for 2–3 min and
transferred to the round bottom flask. The acetone in
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the flask was vaporized in a rotatory evaporator to
leave behind solid Rh-B. This was redissolved in water
with a few drops of methanol (CH3-OH, reagent grade,
Sigma) being added to ensure complete dissolution.
The solutions were analyzed using UV spectroscopy
(Specord 200, Analytik Jena AG, Germany). The spec-
trum was scanned between 450 nm and 750 nm and an
absorption peak was observed around 554 nm.
2.6 Fabrication of microrobot parts
The microrobot parts were fabricated using standard
MEMS photolithography processes and electrodeposi-
tion. A titanium (Ti) adhesion layer of 50 nm and a
copper (Cu) sacrificial layer of 500 nm were deposited
on clean 4 inch silicon wafers using e-beam evaporation
(E306A coating system, Edwards, UK). The wafers
were subsequently patterned using a negative pho-
toresist to produce moulds into which nickel (Ni) was
electrodeposited. A table-top electrodeposition system
(Iko Fibrotools Inc., USA) was used to deposit a 50 μm
thick layer of Ni at a rate of approximately 1 μm.min−1.
Following the electrodeposition, the photoresist was
stripped and the Ni microrobot parts were released by
etching the underlying Cu.
Ni is known to be allergenic and sometimes also car-
cinogenic to humans (Kasprzak et al. 2003). Gold (Au)
coatings show good biocompatibility and are widely
used in dentistry and implants (Zitter and Plent 1987).
In its final form, the microrobot is envisaged to have
a a thin coating of Au in order to ensure that the
bottom layer of the porous functional coating does
not open directly onto Ni. Hence, Ni microrobot parts
were coated with a 250 nm thick layer of Au using an
electroless gold plating bath (Transene Company Inc.,
USA). Some of these gold-coated Ni parts were coated
with the porous PSU using dip coating. The pieces were
dipped into the particle-polymer suspension for 5 min
and then dried in air for 1 min before being immersed
in 1% HCl to remove the particles.
2.7 Biocompatibility tests
The gold coated Ni (Ni-Au) and the porous PSU dip-
coated on gold coated Ni (Ni-Au-PSU) were used in
biocompatibility experiments. Biocompatibility of the
porous PSU coating was established by determining
the viability and adhesion of normal human foreskin
fibroblast (NHDF) cells on the coatings.
Cell viability tests Cell viability was determined by
the water soluble tetrazolium (WST-1) proliferation
and cytotoxicity test. The WST-1 essay has been used
to determine the in-vitro biocompatibility of degrad-
able biopolymers in cell cultures obtained from various
ocular tissues (Huhtala et al. 1998). Upon reaction
with various mitochondrial dehydrogenase enzymes,
the light red colored tetrazolium salt is cleaved to yield
a dark red water soluble dye called formazan which
can be detected using a microplate reader. Therefore,
the greater the amount of formazan detected, the
greater the number of viable and metabolically active
cells.
Proliferating NHDF (PromoCell, Germany) were
harvested from exponentially growing subconfluent
monolayers. The culture was maintained in 25 cm2
culture flasks in Dulbecco’s modified eagle medium
(DMEM, GibcoBRL, Canada) supplemented with
10% heat inactivated fetal bovine serum (FBS, Sigma)
and 1% antibiotic antimycotic (ABAM, GibcoBRL,
Canada) at 37 ◦C and 5% CO2. Cells were used un-
til passage 20. A 2 mg.ml−1 fibrin gel was used to
sustain the NHDF during the course of the biocom-
patibility experiments. Human fibrinogen (Fluka) was
mixed with 125 mM CaCl2, then 2 U.ml−1 of human
thrombin (Sigma) was added as a catalyst to promote
cross-linking of the gel. The gel was then transferred
into a 96-well plate and the microrobot samples were
incubated in this gel along with 3000 NHDF per sample.
Prior to the transfer into the well plate, the Ni, Ni-
Au and Ni-Au-PSU samples were sterilized for 20 min
under UV light and stored in 0.1 M PBS solution at pH
7.4. As controls, 3000 NHDF were incubated with tissue
culture polystyrene (TCPS) and unmodified fibrin gels
under the same conditions. Mitochondrial activity was
measured 24 h after seeding by the addition of 20 μl
WST-1 solution (Roche) per sample and analyzing the
absorption spectrum using a microplate reader (Infinite
M200, Tecan GmbH, Germany).
Cell adhesion tests In order to visualize cell adhe-
sion and cell viability of the NHDF on the surfaces
of the microrobot samples, a live and dead staining
was performed using the fluorescent stains fluorescein
diacetate (FDA, Fluka) and Hoechst 33342 (Invitro-
gen). Living cells metabolize FDA to fluorescein and
Hoechst 33342 intercalates itself with the DNA present
in the nuclei of cells. On individual microrobots, 3000
NHDF were cultured for 48 h and stained with FDA
(1 mg.ml−1, 1:1000) and Hoechst 33342 in a PBS so-
lution for 10 min at room temperature. A FITC filter
and a DAPI filter were used to visualize fluorescein
and Hoechst 33342 respectively under a fluorescence
microscope (Zeiss Axiovert 200M, Carl Zeiss AG,
Germany).
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3 Results and discussions
3.1 Morphology
Figure 4(a) shows the cross section of bulk PSU films.
It can be seen that the film is smooth and does not
exhibit any porosity. Comparing the cross section of
bulk PSU (Fig. 4(a)) with the surface (Fig. 4(b) and
(c)) and the cross section of porous PSU (Fig. 4(d)), it
becomes clear that porosity is not an inherent property
of PSU, but occurs as a consequence of the dissolu-
tion of the embedded CaCO3 nanoparticles. It is also
observed that dip-coated films have fewer openings
on their surface than spin-coated films. Spin coating
enhances the rate of evaporation of the CH2Cl2 solvent,
which rapidly increases the viscosity of the polymer-
particle mixture. This results in the entrapment of a
large amount of nanoparticles on the surface before
they have the chance to sediment, thus creating more
openings on the surface. Also, due to the rotational
forces of the spin coating process, the polymer chains
harden in a centro-symmetric manner, which could
explain the wavy surface of the spin-coated samples
(Yang et al. 1999, Fig. 4(c)).
3.2 Porosity
The chemistry behind the dissolution of the nanoparti-
cles is shown in Eqs. 2 and 3.
CaCO3(s)+2HCl(aq) → CaCl2(aq)+CO2(g)+H2O(l) (2)
CaO(s) + 2HCl(aq) → CaCl2(aq) + H2O(l) (3)
Assuming that HCl dissolves all the embedded





where vparticles and vtotal are the volume of the particles
and volume of the particle-PSU composite, respec-
tively.




× 0.8 + mparticles
ρCaO
× 0.2 (5)
where mparticles is the mass of particles in the composite,
and ρCaCO3 and ρCaO are the densities of CaCO3 and
CaO particles, respectively. Assuming that the volumes




where mPSU and ρPSU are the mass of PSU in the
composite and the density of PSU, respectively.
Based on the ratios and substrate areas mentioned
in Section 2.3, mPSU = 0.105 g and mparticles = 0.095 g.
Using the values, ρCaCO3 = 2.73 g.cm−3, ρCaO =
3.37 g.cm−3, ρPSU = 1.24 g.cm−3, φth is 28.34%.
The porosity was verified experimentally using the
Brunauer–Emmett–Teller (BET) gas adsorption
method (Micrometrics GmbH, Germany). The
Fig. 4 SEM of bulk and
porous PSU. (a) Cross section
of bulk PSU films. (b)
Surface of dip-coated porous
PSU film. (c) Surface of
spin-coated porous PSU film.
(d) Cross section of
spin-coated porous PSU film.
The cross section was typical
of both dip-coated and
spin-coated PSU films
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adsorbate used was nitrogen (N2) at a temperature of
78K (Fig. 5). The measured porosity was 27.8%, which
corroborates the assumption that all the embedded
nanoparticles are dissolved by HCl. The ability to
accurately predict the porosity would be pertinent to
tune the amount of drug that can be loaded on a given
volume of the polymer coating. The average diameter
of the pores as determined by the BET measurements
was around 26 nm which illustrates the nanoporous
nature of the coating and is in good agreement with the
TEM observations (Fig. 1).
3.3 Rhodamine B loading and release
In order to ensure a uniform coating thickness across
all samples, the drug loading and release experiments
were performed only on samples obtained by spin coat-
ing. The thickness of both bulk PSU and porous PSU
coatings obtained was approximately 5 μm. The cu-
mulative release of Rh-B from PSU coatings and bulk
PSU is shown in Fig. 6. The amount of dye released is
normalized over the macroscopic area of the substrate
(2.25 cm2). This was done because the projected area of
a given thickness of both bulk PSU and porous PSU on
the microrobot is the surface area of the microrobot.
Hence, ultimately, the factor constraining the overall
volume of a functional coating for our application is
the macroscopic surface area of the microrobot. The
porous PSU coatings show a fifteen-fold increase in the
amount of Rh-B released compared to their bulk coun-
terparts. The difference between the release behavior
of the porous and bulk PSU indicated that the presence
of pores was a key factor in encapsulation and release of
Rh-B. While the release amount remains constant for
the bulk PSU after the initial 20 to 30 min, the release
Fig. 5 The BET adsorption isotherm for porous PSU mem-
branes. Nitrogen gas (N2) at a temperature of 78 K was used as
the adsorbate. The measured values of porosity and average pore
size were 27.8% and 26 nm, respectively
Fig. 6 Cumulative release graphs showing the average value of
released Rhodamine B from porous PSU and bulk PSU. The
error bars represent standard error of 10 samples over 2 separate
sets of experiments
from the porous PSU does not stabilize for almost 4 h.
This suggests that the Rh-B is not confined to the outer
surface of the porous PSU but percolates through its
network of inter-connected pores, i.e. it is absorbed
instead of just being adsorbed.
Table 1 compares the amount of Rh-B released after
four hours with the estimated amount of dye loaded
onto these membranes. While a significant portion of
the estimated loaded amount of dye is released from
the bulk membranes, only 36% of the amount of dye
loaded onto porous membranes is released. This further
corroborates the hypothesis that inter-connected pores
of the porous membrane results in absorption, and,
consequently to higher loading of the dye.
A common trait in both the porous and bulk PSU
was that a significant amount of dye is released in the
initial 20 min. This can be characterized as a burst
release. Such a release was expected since it was solely
dependent on diffusion. For intraocular drug delivery, a
sustained drug release is required over a period lasting
days to weeks. Such a release profile is usually obtained
by suitably engineering the implant size, implant mate-
rial, and the drug used (Bourges et al. 2006). However,
Table 1 Comparison between the amount of Rhodamine B
loaded and the amount of dye released in PBS after 4 h from
both bulk and porous samples
Membrane Estimated loading % Release
Average St. dev
(n = 5)
Bulk 0.5 0.16 80
Porous 16.5 0.7 36
The estimated amounts indicated are in mg.l−1.cm−2
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Fig. 7 Cell viability of NHDF incubated on various samples. The
viability was determined by analyzing the mitochondrial activity
of the NHDF using a WST-1 assay. The error bars represent
mean values with standard deviation from three independent
experiments carried out in triplicate
the amount of Rh-B loaded onto and released from
the porous PSU compared favorably with the release
rates of three drugs namely, 5-fluorouridine (5FUrd),
triamcinolone (Triam), and human recombinant tissue
plasminogen activator (t-PA) from the biodegradable
ocular implants mentioned in Zhou et al. (1998). Since
dip-coated PSU films obtained in the current work
show fewer pores on their surface than spin-coated
films, dip coating might be an option to suppress this
tendency of burst release. This lack of pores on the sur-
face, however, could lead to a decrease in the amount
of drug that can be loaded onto the membrane. An-
other option to suppress the tendency of burst release
might be adding a layer of bioerodible or biodegradable
polymer onto the spin coated films. By tuning the rate
of bioerosion/biodegradation of the layer, it might also
be possible to obtain a sustained zero order release of
therapeutic agents from the PSU membranes.
3.4 Cell viability tests
The viability of NHDF incubated for 24 h with Ni, Ni-
Au and Ni-Au-PSU is shown in Fig. 7. Since the NHDF
incubated with TCPS and unmodified fibrin gels were
used as controls, the viability data from these controls
were used to normalize the viability data from the other
samples . Cell viability on the bulk PSU was nearly the
same as on the controls, while that on bare Ni was the
poorest. The viability on Ni-Au and Ni-Au-PSU was
significantly better than on bare Ni.
3.5 Live and dead staining
The fluorescence microscope images of the live and
dead staining performed on Ni, Ni-Au and Ni-Au-PSU
(labeled as a, b, c respectively) are shown in Fig. 8.
Green fluorescence from the FDA indicates living cells
while blue fluorescence from Hoechst 33342 indicates
cell nuclei. Despite the allergenic properties of Ni, the
highest cell adhesion was detected on the Ni samples.
The survival of cells on the Ni could be due to the
lack of solvated Ni ions in the culture medium. The
risk of cancer is said to be higher due to the reac-
tion of Ni2+ ions with proteins and aminoacids rather
than just the presence of elemental Ni in the body
(Kasprzak et al. 2003). The International Committee
on Nickel Carcinogenesis in Man suggested that less
soluble forms of Ni pose a risk of cancer when present
in concentrations above 10 mg.m−3 in human beings
(I.A. for Research on Cancer 1990).
The cell adhesion on the Ni-Au-PSU was the lowest.
The low adhesion could be due to the hydrophobic
nature of PSU. The hydrophobicity of bulk PSU is well
established and is around 70◦ (Kim et al. 2002). Static
contact angle measurements on the porous PSU yielded
a value of 97◦ ± 2◦. For applications involving drug
release in the posterior segment of the eye, the lack of
cell adhesion may actually work in favor of the porous
PSU coating. Proliferation of retinal cells is the cause
Fig. 8 Live and dead staining of NHDF on Ni (a), Ni-Au (b) and Ni-Au-PSU (c). Green fluorescence is from live cells while blue
fluorescence is from cell nucleii. PSU coatings show a high degree of autofluorescence
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for eye disorders such as proliferative vitreoretinopathy
(PVR), and cell proliferation in general is the cause for
many post-eye surgery complications (Colthurst et al.
2000). Also, the lack of cell adhesion would prevent
clogging of the pores and, hence, lead to better pre-
dictability of the amount of drug released.
4 Conclusion
A porous, biocompatible, and non-toxic polymeric
coating of polysulfone (PSU) was developed for drug
delivery by selectively dissolving CaCO3 nanoparticles
embedded in bulk PSU coatings. The coating can be
applied by dip or spin coating. The distinct difference in
the morphology of bulk PSU and porous PSU confirms
that the porosity is a result of the selective dissolving
process. The porosity of the coatings as determined by
BET measurements was 27.8% which closely matched
theoretical predictions, thus demonstrating the rela-
tively straightforward nature of synthesis. The suit-
ability of the porous coating for enhanced drug load-
ing and release was tested using Rhodamine B as a
model drug. Although the porous coatings exhibited
a burst drug release profile, they showed an enhanced
adsorption and release which were on average 30 times
and 15 times higher, respectively, compared to their
nonporous counterparts of the same macroscopic vol-
ume. Cell viability tests with human foreskin fibroblast
cells demonstrated that the viability of cells on the
porous PSU is comparable to other commonly used
biocompatible coatings such as gold. Also, cells showed
a low level of adhesion on the porous PSU coatings,
thus making the coating suitable for intraocular drug
delivery.
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